Investors

Press Releases

Press Releases

Date Title View
Toggle Summary Liquidia Technologies Recipient of Best-in-Class Public Offering Award at Southeast BIO
RESEARCH TRIANGLE PARK, N.C. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia Technologies to Present LIQ865 Phase 1a Data at ASRA’s 17th Annual Pain Medicine Meeting
RESEARCH TRIANGLE PARK, N.C. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia Technologies to Present at Jefferies London Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia Technologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Completed enrollment of the safety portion of our Ph3 LIQ861 (INSPIRE) clinical trial Two-week safety Ph3 LIQ861 data readout anticipated in the first quarter of 2019 Dr. Stephen Bloch appointed as Chairman of the Board Management to host webcast and conference call today at 8 a.m.
View HTML
Toggle Summary Liquidia Technologies to Provide Third Quarter 2018 Corporate Update on October 31, 2018
RESEARCH TRIANGLE PARK, N.C. , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT ® technology to transform the
View HTML
Toggle Summary Liquidia Technologies Added to Russell 2000®, 3000® and Microcap® Indexes
RESEARCH TRIANGLE PARK, N.C. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia Technologies to Present at Wedbush PacGrow Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia Technologies Announces Closing of Initial Public Offering
RESEARCH TRIANGLE PARK, N.C. --(BUSINESS WIRE)--Jul. 30, 2018-- Liquidia Technologies, Inc. (the “Company”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of
View HTML
Toggle Summary Liquidia Technologies Announces Pricing of Initial Public Offering
RESEARCH TRIANGLE PARK, N.C. --(BUSINESS WIRE)--Jul. 25, 2018-- Liquidia Technologies, Inc. (the “Company”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT ® technology to transform the lives of
View HTML
Toggle Summary Liquidia Technologies Files Registration Statement for Proposed Initial Public Offering of Common Stock
Liquidia Technologies, Inc. , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced that it has filed a registration statement on Form S-1
View HTML